Orthotopic liver transplantation (OLT) is now a well- established means of restoring health in patients with end stage liver disease. Our long-term objective is to provide evidence- based information to help optimize the outcome of OLT, which is relevant not only at the individual physician and patient level, but also at the health policy level. Building on our achievements from the previous program period and data collaboration from a network of academic transplant centers, we propose to study the three most important issues that face liver transplantation in the United States today.
In specific aim 1, we will prospectively validate the Model for End-stage Liver Disease (MELD) in current OLT candidates. The MELD scale, a liver disease severity index developed by this program, has recently been adopted by the United Network for Organ Sharing (UNOS) as the national liver allocation system for OLT. Our central hypothesis is that the addition of further variables to the model will not materially improve the model, except in patients with hepatocellular carcinoma, in whom the risk of tumor progression needs to be considered in addition to the severity of underlying liver disease.
In specific aim 2, we will identify determinants of the outcome of recurrent hepatitis C following OLT. OLT recipients with hepatitis C, the most common indication for the procedure today, have shorter survival and poorer quality of life. Our hypothesis is that pretransplant alcohol consumption and post-transplant obesity affect the rate of progression of recurrent hepatitis C and thus, the outcome.
In specific aim 3, we will study the cardiovascular morbidity in long-term survivors following OLT. Based on the number of patients and length of follow-up available in our database, we will identify traditional (e.g., diabetes, hypertension, and hyperlipidemia) and transplant-specific (e.g., cytomegalovirus infection and liver disease diagnosis) risk factors that are associated with cardiovascular complications. The results of these studies will provide relevant information not only to clinicians in practice, but also transplantation policy makers. The feasibility of the proposed projects is supported by the extensive experience and track record of this program in creating and maintaining a large, multicenter, liver transplant database and strong statistical expertise.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK034238-19
Application #
6821370
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Everhart, James
Project Start
1986-01-15
Project End
2006-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
19
Fiscal Year
2005
Total Cost
$408,122
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Heo, Nae-Yun; Mannalithara, Ajitha; Kim, Donghee et al. (2018) Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States. Transplantation 102:454-460
Kwong, Allison J; Kim, W Ray; Flemming, Jennifer A (2018) De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. Hepatology 68:1288-1297
Yang, Ju Dong; Mannalithara, Ajitha; Piscitello, Andrew J et al. (2018) Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 68:78-88
Kwong, Allison J; Goel, Aparna; Mannalithara, Ajitha et al. (2018) Improved posttransplant mortality after share 35 for liver transplantation. Hepatology 67:273-281
Allen, Alina M; Heimbach, Julie K; Larson, Joseph J et al. (2018) Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation 102:1710-1716
Kwong, Allison; Kim, W Ray; Mannalithara, Ajitha et al. (2018) Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. Liver Transpl 24:735-743
Flemming, Jennifer A; Kim, W Ray; Brosgart, Carol L et al. (2017) Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 65:804-812
Kim, Sang Gyune; Larson, Joseph J; Lee, Ji Sung et al. (2017) Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl 23:733-740
Laskey, Heather L; Schomaker, Nathan; Hung, Kenneth W et al. (2016) Predicting renal recovery after liver transplant with severe pretransplant subacute kidney injury: The impact of warm ischemia time. Liver Transpl 22:1085-91
Udompap, Prowpanga; Mannalithara, Ajitha; Heo, Nae-Yun et al. (2016) Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol 64:1027-1032

Showing the most recent 10 out of 95 publications